Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)

被引：4
作者：
Cheema, P. [1 ]
Passaro, A. [2 ]
Martin, C. [3 ]
Tiseo, M. [4 ]
Park, K. [5 ]
Chang, G. [6 ,7 ,8 ]
Hu, Y. [9 ]
Cho, B. C. [10 ]
Miranda, M. [11 ]
Fernandes, A. [12 ]
Freitas, H. [13 ]
机构：
[1] Univ Toronto, Sunnybrook Odette Canc Ctr, William Osler Hlth Syst, Toronto, ON, Canada
[2] European Inst Oncol Irccs, Ieo, Div Thorac Oncol, Milan, Italy
[3] Inst Alexander Fleming, Dept Oncol, Buenos Aires, DF, Argentina
[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea
[6] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan
[7] Taichung Vet Gen Hosp, Fac Med, Sch Med, Taichung, Taiwan
[8] Natl Yang Ming Univ, Taichung, Taiwan
[9] Hubei Canc Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[11] Astrazeneca, Biometr & Informat Sci, Cambridge, England
[12] Astrazeneca Us, Gaithersburg, MD USA
[13] AC Camargo Canc Ctr, Clin Res Unit, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; EGFR; Osimertinib;
D O I：
10.1016/j.jtho.2019.08.1844
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14-59
引用
收藏
页码：S854 / S854
页数：1
相关论文
共 50 条
  • [1] ASTRIS: A Real World Study of Osimertinib Treatment in Patients with EGFR T790M Positive Advanced NSCLC; Interim Analysis
    Kim, S.
    Cho, B. C.
    Kim, D.
    Park, K.
    Tiseo, M.
    Migliorino, M. R.
    Santo, A.
    Lee, J.
    Vicente, D.
    Paredes, A.
    O'Hanrahan, E.
    Freitas, H.
    Provencio, M.
    Chen, Y.
    Cheema, P.
    Milner, A.
    Rigas, J.
    Wu, Y.
    De Marinis, F.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2202 - S2202
  • [2] Osimertinib Real-World Experience in EGFR T790M Positive Locally Advanced or Metastatic NSCLC in Taiwan
    Chang, G.
    Shih, J.
    Chao, H.
    Yang, C.
    Lin, C.
    Hung, J.
    Hsiao, S.
    Wang, C.
    Chian, C.
    Hsia, T.
    Yu, C.
    Chen, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S679 - S679
  • [3] ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
    Zhou, Q.
    Zhang, H. -L.
    Jiang, L. -Y.
    Shi, Y. -K.
    Chen, Y.
    Yu, J. -M.
    Zhou, C. -C.
    He, Y.
    Hu, Y. -P.
    Liang, Z. -A.
    Pan, Y. -Y.
    Zhuo, W. -L.
    Song, Y.
    Wu, G.
    Chen, G. -Y.
    Lu, Y.
    Zhang, C. -Y.
    Zhang, C. -Y.
    Zhang, Y. -P.
    Chen, Y.
    Lu, S.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S430
  • [4] A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data
    Cheema, Parneet
    Cho, Byoung Chul
    Freitas, Helano
    Provencio, Mariano
    Chen, Yuh Min
    Kim, Sang-We
    Wu, Yi-Long
    Passaro, Antonio
    Martin, Claudio
    Tiseo, Marcello
    Chang, Gee-Chen
    Park, Keunchil
    Solomon, Benjamin
    Burghuber, Otto
    Laskin, Janessa
    Wang, Ziping
    Lee, Sung Yong
    Hu, Yanping
    Vansteenkiste, Johan
    Zhang, He-long
    Hanrahan, Emer
    Geldart, Thomas
    Taylor, Rosemary
    Servidio, Leslie
    Li, Jingyi
    de Marinis, Filippo
    FUTURE ONCOLOGY, 2023, 19 (01) : 61 - 75
  • [5] Monitoring of EGFR Mutations During Osimertinib Treatment in Advance EGFR-Mutant T790M Positive NSCLC
    Mohorcic, K.
    Janzic, A.
    Janzic, U.
    Rot, M.
    Kern, I.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S557 - S558
  • [6] Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis
    Cheema, P.
    Liu, G.
    Burkes, R.
    Owen, S.
    Yu, J.
    Hao, D.
    Rothenstein, J.
    Martel, S.
    Iqbal, M.
    Juergens, R.
    Lam, W.
    Laskin, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S803 - S803
  • [7] Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysis
    Galvez-Nino, Marco
    Roque, Katia
    Ruiz, Rossana
    Namuche, Fernando
    Paitan, Victor
    Arrese, Tulio
    Zegarra, Jorge
    Oblitas, George
    Gonzalez, Lisde
    Maco, Lorenzo
    Cabrera, Maria del Pilar
    Coello, Roberto
    Pino, Jose Luis Portugal del
    Ezquerra, Juan Carlos
    Roca, Rodolfo Perez
    Coanqui, Ofelia
    Valdiviezo, Natalia
    Olivera, Mivael
    Vidaurre, Tatiana
    Cartagena, Alfredo Aguilar
    Mas, Luis
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2025, 43
  • [8] ASTRIS a RWT with Osimertinib in NSCLC EGFR T790M Mutated: Disease Characteristics from Patients Included in Argentina
    Biolchi, M.
    Recondo, G.
    Casalnuovo, M.
    Tsou, F.
    Diaz Perez, I.
    Reinhold, F.
    Martin, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S169 - S169
  • [9] ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer
    de Marinis, Filippo
    Wu, Yi-Long
    de Castro Jr, Gilberto
    Chang, Gee-Chen
    Chen, Yuh-Min
    Cho, Byoung Chul
    Freitas, Helano C.
    Jiang, Liyan
    Kim, Sang-We
    Martin, Claudio
    Metro, Giulio
    Provencio, Mariano
    Vansteenkiste, Johan
    Vicente, David
    Zhou, Qing
    Miranda, Miguel F.
    Bakker, Nicolaas A.
    Rigas, James R.
    Cheema, Parneet K.
    FUTURE ONCOLOGY, 2019, 15 (26) : 3003 - 3014
  • [10] Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example
    Wei, Bing
    Zhao, Chengzhi
    Li, Jun
    Zhao, Jiuzhou
    Ren, Pengfei
    Yang, Ke
    Yan, Chi
    Sun, Rui
    Ma, Jie
    Guo, Yongjun
    MOLECULAR ONCOLOGY, 2019, 13 (05) : 1226 - 1234
12345